CN105324387A - 具有稠环邻烷氧基取代的芳基膦 - Google Patents
具有稠环邻烷氧基取代的芳基膦 Download PDFInfo
- Publication number
- CN105324387A CN105324387A CN201480034103.8A CN201480034103A CN105324387A CN 105324387 A CN105324387 A CN 105324387A CN 201480034103 A CN201480034103 A CN 201480034103A CN 105324387 A CN105324387 A CN 105324387A
- Authority
- CN
- China
- Prior art keywords
- group
- unsubstituted
- substituted
- carbon
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Aryl phosphines Chemical class 0.000 title claims abstract description 51
- 238000006467 substitution reaction Methods 0.000 title abstract 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 68
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims abstract description 55
- 125000003118 aryl group Chemical group 0.000 claims abstract description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 229910052723 transition metal Inorganic materials 0.000 claims description 14
- 150000003624 transition metals Chemical class 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 11
- 239000011651 chromium Substances 0.000 claims description 10
- 239000010949 copper Substances 0.000 claims description 10
- 239000010948 rhodium Substances 0.000 claims description 10
- 239000010936 titanium Substances 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000004437 phosphorous atom Chemical group 0.000 claims description 6
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 5
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 229910017052 cobalt Inorganic materials 0.000 claims description 5
- 239000010941 cobalt Substances 0.000 claims description 5
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 229910052763 palladium Inorganic materials 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 229910052703 rhodium Inorganic materials 0.000 claims description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims description 5
- 229910052719 titanium Inorganic materials 0.000 claims description 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 238000003756 stirring Methods 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 238000004679 31P NMR spectroscopy Methods 0.000 description 23
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 17
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- ORPNDFMZTDVBGA-UHFFFAOYSA-N (2-methoxyphenyl)phosphane Chemical compound COC1=CC=CC=C1P ORPNDFMZTDVBGA-UHFFFAOYSA-N 0.000 description 13
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910052794 bromium Inorganic materials 0.000 description 9
- 238000006555 catalytic reaction Methods 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000004810 polytetrafluoroethylene Substances 0.000 description 7
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 7
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 6
- 0 CCc1ccc(*)cc1 Chemical compound CCc1ccc(*)cc1 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000607 proton-decoupled 31P nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 description 5
- GBXNVYBGIFEOEM-UHFFFAOYSA-N (2-methoxyphenyl)-diphenylphosphane Chemical compound COC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 GBXNVYBGIFEOEM-UHFFFAOYSA-N 0.000 description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 4
- 101100457838 Caenorhabditis elegans mod-1 gene Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 101150110972 ME1 gene Proteins 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000007037 hydroformylation reaction Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- VGOUXHRZQNPOPY-UHFFFAOYSA-N 7-bromo-2,3-dihydro-1-benzofuran Chemical class BrC1=CC=CC2=C1OCC2 VGOUXHRZQNPOPY-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- XGRJZXREYAXTGV-UHFFFAOYSA-N chlorodiphenylphosphine Chemical compound C=1C=CC=CC=1P(Cl)C1=CC=CC=C1 XGRJZXREYAXTGV-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000006880 cross-coupling reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229910003002 lithium salt Inorganic materials 0.000 description 3
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 3
- ZFJMTDFOGDGPTF-UHFFFAOYSA-N phosphanium;chloride;hydrochloride Chemical compound P.Cl.Cl ZFJMTDFOGDGPTF-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XFGLBBQXQQOWGO-UHFFFAOYSA-N 2,2-dimethyl-5-phenyl-1h-1,4-benzodiazepin-3-one Chemical compound N=1C(=O)C(C)(C)NC2=CC=CC=C2C=1C1=CC=CC=C1 XFGLBBQXQQOWGO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000016941 Rho Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- WDOKISJWRVNYNS-UHFFFAOYSA-N dicyclohexylphosphanium;chloride Chemical compound Cl.C1CCCCC1PC1CCCCC1 WDOKISJWRVNYNS-UHFFFAOYSA-N 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
- MCRSZLVSRGTMIH-UHFFFAOYSA-N ditert-butyl(chloro)phosphane Chemical compound CC(C)(C)P(Cl)C(C)(C)C MCRSZLVSRGTMIH-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 239000012041 precatalyst Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HITROERJXNWVOI-SOFGYWHQSA-N (5e)-octa-1,5-diene Chemical compound CC\C=C\CCC=C HITROERJXNWVOI-SOFGYWHQSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- NOAWYGGJZRZBCV-FBAUCUACSA-N C(C1)[C@@H](C2)CC3C1CCC2C3 Chemical compound C(C1)[C@@H](C2)CC3C1CCC2C3 NOAWYGGJZRZBCV-FBAUCUACSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- NAVPCEPWGWJZHD-UHFFFAOYSA-N Cc(cc1C)cc(C)c1N1C=CNC1 Chemical compound Cc(cc1C)cc(C)c1N1C=CNC1 NAVPCEPWGWJZHD-UHFFFAOYSA-N 0.000 description 1
- NAVPCEPWGWJZHD-UHFFFAOYSA-P Cc(cc1C)cc(C)c1[NH+]1C=C[NH2+]C1 Chemical compound Cc(cc1C)cc(C)c1[NH+]1C=C[NH2+]C1 NAVPCEPWGWJZHD-UHFFFAOYSA-P 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- DBMZFQMDCCKTFM-UHFFFAOYSA-N [Cl-].FC(C=1C=C(C=C(C1)C(F)(F)F)[PH3+])(F)F Chemical compound [Cl-].FC(C=1C=C(C=C(C1)C(F)(F)F)[PH3+])(F)F DBMZFQMDCCKTFM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N c(cc1)ccc1-c1ccccc1 Chemical compound c(cc1)ccc1-c1ccccc1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- GGRQQHADVSXBQN-FGSKAQBVSA-N carbon monoxide;(z)-4-hydroxypent-3-en-2-one;rhodium Chemical compound [Rh].[O+]#[C-].[O+]#[C-].C\C(O)=C\C(C)=O GGRQQHADVSXBQN-FGSKAQBVSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- GYQSSCGWAJWHCK-UHFFFAOYSA-N dimethylaminophosphanium;chloride Chemical compound [Cl-].CN(C)[PH3+] GYQSSCGWAJWHCK-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- OCVXZQOKBHXGRU-UHFFFAOYSA-N iodine(1+) Chemical compound [I+] OCVXZQOKBHXGRU-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- TZMFJUDUGYTVRY-UHFFFAOYSA-N pentane-2,3-dione Chemical compound CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- WJIBZZVTNMAURL-UHFFFAOYSA-N phosphane;rhodium Chemical compound P.[Rh] WJIBZZVTNMAURL-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
- B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
- B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
- B01J31/2457—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings, e.g. Xantphos
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
- B01J31/2414—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2419—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
- B01J31/2428—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom
- B01J31/2433—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/006—Palladium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
- C07F15/008—Rhodium compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5045—Complexes or chelates of phosphines with metallic compounds or metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65525—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring
- C07F9/65527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/20—Olefin oligomerisation or telomerisation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/824—Palladium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2540/00—Compositional aspects of coordination complexes or ligands in catalyst systems
- B01J2540/10—Non-coordinating groups comprising only oxygen beside carbon or hydrogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
一种具有稠环邻烷氧基取代的芳基膦,所述芳基膦包括芳基单膦和芳基双膦。
Description
技术领域
本公开涉及具有稠环邻烷氧基取代的芳基膦。
背景技术
含磷(P)化合物是多种过渡金属的配体,所述过渡金属包括但不限于钛(Ti)、铜(Cu)、钯(Pd)、钴(Co)、铑(Rh)、钌(Ru)、铬(Cr)和铂(Pt)。具体地,含P化合物(如包括共价键结到芳环的P原子的芳基膦)是多种过渡金属催化反应的配体。这些过渡金属催化反应可包括氢化反应、乙烯和一氧化碳共聚反应、丁二烯调聚反应、加氢甲酰化反应、金属(例如,Pd)催化的交叉偶合(例如,铃木反应(Suzukireaction)、布赫瓦尔德-哈特维希偶合反应(Buchwald-Hartwigcouplingreaction))、烯烃的甲氧羰基化、乙烯齐聚,以及烯烃聚合。
当芳基膦被用作这些过渡金属催化反应中一个反应的配体时,可通过改变瞵芳环上的取代基来改变过渡金属催化剂周围的电子和空间环境。举例来说,芳基膦的芳环上的邻烷氧基取代被视为供电子基并且已经显示出对于多种工业相关转化的价值(关于丁二烯调聚反应的WO2011101504;关于交叉偶合的《美国化学学会期刊》(J.Am.Chem.Soc.)2008,130,13552;关于乙烯和一氧化碳共聚合的《分子催化期刊》(J.Mol.Cat.)A2007,265,292-305)。然而,官能团放置在邻芳基位置改变了催化剂周围的空间参数,这在有些情况下会不利地影响催化剂性能。
发明内容
本公开提供了意外发现,即具有稠环邻烷氧基取代的芳基膦允许与邻烷氧基(例如,供电子基)有关的电子益处,同时相较于没有稠环的烷氧基减少了催化剂周围的空间体积,从而使得能够增强包含此芳基膦作为配体的催化剂的性能。增强的性能可以指代更高的反应速率、更高的试剂转化率、增强的催化剂转换数、更长的催化剂寿命,和/或相对于副产物对所需产物增强的选择性。
本公开提供芳基膦,其包含键结到芳基的1个P原子;以及芳基双膦,其包含第一芳基膦通过桥连基键结到第二瞵。本公开尤其提供式(I)的具有稠环邻烷氧基取代的芳基膦:
所述芳基膦包括芳基上的稠环邻烷氧基取代基,所述稠环邻烷氧基取代基通过相对于到所述芳基的磷键的邻位处的氧原子和相邻间位处的碳原子而共价键结到所述芳基。所述稠环邻烷氧基取代基形成环状结构,如式(I)所示,其中n是在1至3范围内的整数,从而提供具有4至6个碳构造和一个氧原子的环状结构。R2和R2′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组。R1和R3选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组。
R4和R5可独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳并且优选地具有3至10个碳的经取代或者未经取代的环烷基,卤素、芳基,以及经取代或者未经取代的苯环组成的群组。卤素选自由氯(Cl)、溴(Br)、碘(I)和氟(F)组成的群组。当R4和/或R5是烷基时,R4和R5可独立地选自由甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基组成的群组。当R4和/或R5是环烷基时,R4和R5可独立地选自由金刚烷基和环己基组成的群组。R4和R5可独立地选自由经取代或者未经取代的苯基和经取代或者未经取代的联苯基组成的芳基。
R6和R7独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳的经取代或者未经取代的环烷基,卤素,以及经取代或者未经取代的苯环组成的群组。卤素选自由Cl、Br、I和F组成的群组。
关于R1、R2、R2′、R3、R4、R5、R6或者R7的经取代结构,取代基可包括含有选自由氧(O)、氮(N)、卤素、硫(S)、硼(B)、P以及硅(Si)组成的群组的杂原子。举例来说,官能团可包括F3C-、FCH2O-、F2HCO-、F3CO-、R3Si、B(OR)2、RO、RS、RS(O)、RS(O)2、R2P、R2N、R2C=N、NC、RC(O)O、ROC(O)、RC(O)N(R),或者R2NC(O)。
R3和R7还可组合成环状结构,如式(II)所示:
当R3和R7组合而形成式(II)的环状结构时,R3是烃氧基而R7是烷基,其中n是整数,如本文所论述的,R1、R2和R2′独立地选自本文所论述的群组。因此,邻烷氧基可键结至式(I)中芳环的任一侧。
R4和R5可独立地选自由甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、金刚烷基、苯基、联苯基以及环己基组成的群组。所述芳基膦的P原子可与R4和R5一起形成5员、6员或者7员环。举例来说,芳基膦的P原子可为由4至6个范围内的碳形成的环状结构的成员。此外,环状结构可包括杂原子,如本文所论述的那些。
R4可独立地选自由式(III)至式(XI)组成的群组:
或者
在式(III)中,m是1或者2,因此键结至芳基的环可包括4或者5个碳。在式(III)中,Q1和Q2独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳的经取代或者未经取代的环烷基、卤素,以及经取代或者未经取代的苯环组成的群组。Q3选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组。Q4和Q4′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组。
在式(IV)中,Q5选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳并且优选地具有3至10个碳的经取代或者未经取代的环烷基、卤素,以及经取代或者未经取代的苯环组成的群组。在式(IX)中,u是在0至2范围内的整数;并且在式(X)中,v是在0至2范围内的整数。
当R4和R5都为式(XI)时,R4和R5任选地在相对于式(XI)中的O原子和苯基之间的键的邻位处共价键结在一起。举例来说,当R4和R5在式(XI)中相应C原子的邻位处共价键结在一起时,形成了包括式(I)的P原子、2个氧原子和4个碳原子的环,如式(XLI)中所示。
式(I)的具体但是非限制性实例包括以下式(XII)至式(XXVIII),所述实例可充当催化反应(包括但不限于丁二烯(C4H6)调聚反应)的配体:
式(I)的具体但是非限制性实例包括以下式(XXIX)至式(XXXV),所述实例可充当催化反应(包括但不限于Pd催化的交叉偶合)的配体:
式(I)的具体但是非限制性实例包括以下式(XXXVI)至式(XLII),所述实例可充当催化反应(包括但不限于甲氧羰基化和/或加氢甲酰化)的配体:
式(I)的具体但是非限制性实例包括下式(XLIII),所述实例可用作合成其它配体的合成前体:
如本文所论述的,芳基膦可为芳基双膦,其中第一芳基膦通过桥连基键结至第二瞵。举例来说,R5可为包括芳环并且将式(I)的芳基膦连接至式(I)的第二芳基膦的桥连基。R5可选自由式(XLIV)至式(LIX)组成的群组:
或者
在式(LVIII)中,iPr被定义为异丙基。在前述式(XLIV)至式(LIX)中,Z是式(I)的芳基膦,从而形成双膦,其中两个芳基膦通过式(XLIV)至式(LIX)中的一个连接。当R5是桥连基时,R4可为但不限于式(III)。R8和R9独立地选自H和具有4个碳的烷基。R10选自由C和S组成的群组。R11选自由O和S组成的群组。R12、R13、R14和R15各自独立地选自由C和O组成的群组。R16选自由N和C组成的群组,限制条件是当R16是N时则R14和R15是C。
式(I)的具体实例包括以下式(LX)至式(LXXVI),所述实例可充当甲氧羰基化和/或加氢甲酰化的配体:
式(I)的具体实例包括以下式(LXXVII),所述实例可充当乙烯齐聚的配体:
R5可为包括芳环并且可将式(I)的芳基膦连接至第二芳基膦的桥连基。R5和第二瞵可一起形成选自由式(LXXVIII)至式(LXXX)组成的群组的结构:
式(I)的具体实例包括以下式(LXXXI)至式(LXXXIII),所述实例可充当甲氧羰基化和/或加氢甲酰化的配体:
或者
本文所论述的芳基膦是多种过渡金属的配体。举例来说,本文论述的芳基膦是过渡金属的配体,所述过渡金属选自由钛(Ti)、铜(Cu)、钯(Pd)、钴(Co)、铑(Rh)、钌(Ru)、铬(Cr)和铂(Pt)组成的群组。因此,本公开的配体包括如本文所提供的芳基膦,以及选自由钛(Ti)、铜(Cu)、钯(Pd)、钴(Co)、铑(Rh)、钌(Ru)、铬(Cr)和铂(Pt)组成的群组的过渡金属。
具体实施方式
实例
除非另有说明,否则在氮气气氛下进行所有反应。除非另有说明,否则在实例中使用的所有反应物和试剂是从公司购得。除非另有说明,否则在所有反应中使用脱气的反渗透水(水)。7-溴-2,3-二氢苯并呋喃(根据克里根(Kerrigan),F.;马丁(Martin),C.;托马斯(Thomas),G.H.,《四面体通讯》(TetrahedronLett.),1998,39,2219(克里根)合成);二叔丁基氯化膦(舒奇蒙(Strem)公司)、二环己基氯化膦(舒奇蒙公司)、8-溴色满(根据克里根合成);9-溴-2,3,4,5-四氢苯并[b]噁庚因(oxepine)(根据克里根合成);氯双(2-甲氧苯基)膦(阿法埃莎公司(AlfaAesar));氯化烯丙基钯(II)二聚物(舒奇蒙公司);甲苯(费舍尔公司(Fisher))。
用以下四种分光光度计中的一种获得质子、碳-13、磷-31NMR和19F光谱:(1)瓦里安(Varian)MercuryVXR-300;(2)瓦里安MercuryVX-400;(3)瓦里安MR-400,或者(4)瓦里安VNMRS-500。化学位移是相对于溶剂峰的百万分率(ppm):CDCl3中CHCl3的1H=7.25,而C6D6中C6HD5的1H=7.16;CDCl3的13C=77.23,而C6D6的13C=128.39。
包含稠环邻烷氧基取代的芳基膦的实例(APEx)1:二叔丁基(2,3-二氢苯并呋哺-
7-基)膦
如下所述制备APEx1。将二氢苯并呋喃(2.6克(g),8.3毫摩尔(mmol))添加到具有涂覆聚四氟乙烯(PTFE)的搅拌棒的玻璃瓶中。搅拌玻璃瓶中的内含物并且添加乙醚(40毫升(mL))以溶解二氢苯并呋喃。逐滴添加正丁基锂(n-BuLi)(9.1mL,2.5摩尔浓度(M)己烷溶液)到玻璃瓶的搅拌内含物中。在23℃下搅拌玻璃瓶的内含物22小时(hr)。在真空中从玻璃瓶的内含物去除除10mL以外的所有溶剂。通过从橙色油状物轻轻倒出剩余溶剂来分离出橙色油状物。在真空下干燥所述橙色油状物以得到芳基锂(1.47g,11.4mmol)。
添加芳基锂(1.47g)和乙醚(40mL)到第二玻璃瓶中以溶解芳基锂。将第二玻璃瓶中的内含物放置在冷冻机中-40℃下10分钟。从冷冻机中拿出第二玻璃瓶并且逐滴添加二叔丁基氯化膦(2.2mL,11.4mmol)到第二玻璃瓶的内含物中。搅拌第二玻璃瓶的内含物20小时。添加40mL的水到第二玻璃瓶的内含物中以淬灭反应。分离有机层并且用20mL的水冲洗。经MgSO4干燥有机层,过滤,并且放置在真空下以去除溶剂。在10mL甲醇(MeOH)中悬浮油状白色固体,并且将悬浮液放置在冷冻机中-40℃下30分钟。分离固体并且在真空下干燥以得到白色固体形式的APEx1(0.79g)。
用1H、13C和31P核磁共振光谱法分析APEx1以证实形成。1HNMR(400MHz,CD2Cl2)δ7.40(b,1H),7.19(d,J=6.9Hz,1H)),6.80(t,J=6.5Hz,1H),4.49(t,J=8.4Hz,2H),3.20(t,J=8.7Hz,2H),1.19(d,JP-H=11.8Hz,18H);13CNMR(101MHz,CD2Cl2)δ165.8(b,1C),134.1(s,1CH),127.3(s,C),126.1(b,1CH),120.0(s,1CH),117.9(d,J=28Hz,1C),70.8(s,1CH2),32.6(d,J=22Hz,2C),30.9(d,J=15Hz,6CH3),30.4(s,1CH2);31PNMR(162MHz,CD2Cl2)δ51.1(37%的构象异构体A),11.5(63%的构象异构体B)。已经针对相关结构识别出两个构象异构体在23℃下共存(《有机金属化合物》(Organometallics),2007,26,3585-3596)。
APEx2:双(3,5-双(三氟甲基)苯基)(2,3-二氢苯并呋喃-7-基)膦
如下所述制备APEx2。添加二氢苯并呋喃(2.65g)到具有涂覆PTFE的搅拌棒的玻璃瓶中。搅拌玻璃瓶的内含物并且添加乙醚(40mL)以溶解二氢苯并呋喃。逐滴添加n-BuLi(8.8mL,2.5M己烷溶液)到玻璃瓶的搅拌内含物中。在23℃下搅拌玻璃瓶的内含物22小时。在真空中从玻璃瓶的内含物去除90%的溶剂。添加己烷到玻璃瓶的内含物中。通过从油状固体轻轻倒出剩余的溶剂来分离所得的油状固体。用己烷冲洗油状固体两次。在真空下干燥所述油状固体以得到固体(1.11g)。
在第二玻璃瓶中在乙醚(40mL)中悬浮所述固体(0.80g)。将第二玻璃瓶的内含物放置在冷冻机中-40℃下10分钟。将先前已经储藏在冷冻机中-40℃下的乙醚(10mL)和双(3,5-二(三氟甲基)苯基)氯化膦(2.0g)的溶液逐滴添加到第二玻璃瓶的内含物中。通过间或地停止添加试剂并且将所述试剂放回冷冻机中5至10分钟来维持反应温度摸起来是冷的。将涂覆PTFE的搅拌棒添加到第二玻璃瓶的内含物中并且搅拌过夜。添加20mL的水到所述瓶的内含物中。用另外的20mL的水冲洗有机层。分离所述有机层,经MgSO4干燥,过滤,并且在真空中去除剩余溶剂。从MeOH分离出橙色沉淀。在真空下干燥所述橙色沉淀3小时以形成APEx2(0.74g)。
用1H、13C、31P和19F核磁共振光谱法分析APEx2以证实形成。1HNMR(400MHz,CD2Cl2)δ7.92(s,2H),7.88(s,2H),7.86(s,2H),7.37(d,J=7.4Hz,1H),7.00(t,J=7.5Hz,1H),6.92(t,J=7.4Hz,1H),4.47(t,J=8.7Hz,2H),3.24(t,J=8.7Hz,2H);13C{1H}NMR(101MHz,CD2Cl2)δ163.2(d,J=7Hz,C),140.0(d,J=17Hz,C),134.4(s,CH),134.2(s,CH),134.0(d,J=22Hz,CH),132.2(qd,J=33,6Hz,CCF3),128.8(s,CH),128.8(s,C),123.9(q,J=273Hz,CF3),123.7(m,CH),122.1(d,J=8Hz,CH),119.9(s,C),113.0(d,J=13Hz,C),72.2(s,CH2),30.1(s,CH2);31P{1H}NMR(162MHz,CD2Cl2)δ-9.9(s);19FNMR(376MHz,CD2Cl2)δ-63.8(s)。
APEx3:二环己基(2,3-二氢苯并呋喃-7-基)膦
如下所述制备APEx3以得到芳基锂(1.79g)。重复APEx1,但是变化为添加二氢苯并呋喃(2.65g)到玻璃瓶中。在23℃下搅拌所述玻璃瓶的内含物20小时。
添加芳基锂(1.79g)和乙醚(40mL)到第二玻璃瓶中以溶解芳基锂。将第二玻璃瓶的内含物放置在冷冻机中-40℃下10分钟。将涂覆PTFE的搅拌棒添加到第二玻璃瓶的内含物中并且在搅拌的同时添加二环己基氯化膦(2.6mL,11.9mmol)。在23℃下搅拌第二玻璃瓶的内含物过夜。添加30mL的水到第二玻璃瓶的内含物中以淬灭反应。分离有机层并且用20mL的水冲洗。经MgSO4干燥有机层,过滤,并且放置在真空下以去除溶剂。添加热(约50℃)MeOH到第二玻璃瓶的内含物中以悬浮油状物。从所述油状物中轻轻倒出热MeOH。再次添加热(约50℃)MeOH到第二玻璃瓶的内含物中以悬浮油状物。从所述油中轻轻倒出热MeOH,并且将第二玻璃瓶的内含物在冷冻机中-40℃下冷却以产生固体形式的APEx3(0.69g)。
用1H、13C和31P核磁共振光谱法分析APEx3以证实形成。1HNMR(400MHz,CD2Cl2)δ7.18(m,2H),6.82(t,J=7.4Hz,1H),4.52(t,J=8.8Hz,2H),3.19(t,J=8.7Hz,2H),2.11(m,2H),1.55-1.95(m,10H),0.95-1.4(m,10H);13C{1H}NMR(101MHz,CD2Cl2)峰未识别出δ164.44,164.37,134.80,134.62,127.12,125.97,120.40,120.34,116.31,116.09,71.13,33.34,33.22,31.35,31.17,30.30,30.12,30.04,27.87,27.74,27.67,27.12;31P{1H}NMR(162MHz,CD2Cl2)δ-5.3(s)。
APEx4:色满-8-基双(2-甲氧苯基)膦
如下所述制备APEx4。将已在干冰/丙酮浴中冷却的含8-溴色满(407mg,1.91mmol)的无水四氢呋喃(THF,10mL)添加到具有涂覆PTFE的搅拌棒的玻璃瓶中。搅拌玻璃瓶的内含物并且逐滴添加n-BuLi(2.5M己烷溶液,0.76mL,1.9mmol)。在-78℃下搅拌玻璃瓶的内含物1.5小时。经10分钟(min)的过程添加氯双(2-甲氧苯基)膦(482mg,1.72mmol)在无水THF(15mL)中的悬浮液。使玻璃瓶的内含物加温到23℃。在23℃下搅拌玻璃瓶的内含物2小时,并且用旋转式蒸发仪去除挥发性组分。用水(10mL)淬灭反应,并且用二氯甲烷(DCM)洗涤。经MgSO4干燥有机层,过滤,并且用旋转式蒸发仪去除挥发性组分。将有机层、温乙醇(55mL,50℃)和DCM(8mL)添加到第二玻璃瓶中以使所述有机层再结晶。从母层收集2批晶体以得到结晶形式的APEx4(359mg,55%的产率)。
用1H、13C和31P核磁共振光谱法分析APEx4以证实形成。1HNMR(400MHz,CDCl3)δ7.32(t,J=7.7Hz,2H),7.03(d,J=7.5Hz,1H),6.94-6.77(m,4H),6.71(t,J=5.6Hz,3H),6.53-6.42(m,1H),4.10(明显的t,J=5.0Hz,2H),3.75(s,6H),2.81(t,J=6.4Hz,2H),1.95(dt,J=11.4,5.7Hz,2H);13CNMR(101MHz,CDCl3)δ161.61(d,J=16.8Hz),133.84(s),131.54(s),130.38(s),129.80(s),124.93(d,J=13.5Hz),123.63(d,J=12.8Hz),120.81(s),119.98(s),110.18(s),66.59(s),55.76(s),25.07(d,J=1.7Hz),22.31(s);31PNMR(162MHz,CDCl3)δ-38.86(s)。
APEx5:2,3-二氢苯并呋喃-7-基)二苯基膦
重复APEx4,但是变化为:添加7-溴-2,3-二氢苯并呋喃(200mg,1.0mmol)而不是8-溴色满,并且添加纯的二苯基氯化膦(0.19mL,1.0mmol)而不是氯双(2-甲氧苯基)膦,以产生白色粉末形式的APEx5(129mg,45%的产率)。
用1H、13C和31P核磁共振光谱法分析APEx5以证实形成。1HNMR(400MHz,CDCl3)δ7.49-7.34(m,10H),7.26(dd,J=7.2,0.8Hz,1H),6.84(t,J=7.5Hz,1H),6.69(dd,1H),4.59(t,J=8.7Hz,2H),3.26(t,J=8.7Hz,2H);13CNMR(101MHz,CDCl3)δ162.44(d,J=16.7Hz),136.06(d,J=10.0Hz),133.58(d,J=19.8Hz),131.84(s),128.49(s),128.26(d,J=7.0Hz),126.26(d,J=2.8Hz),125.62(s),120.66(s),116.93(d,J=13.4Hz),71.12(s),29.48(s);31PNMR(162MHz,CDCl3)δ-18.50(s)。
APEx6:2,3-二氧苯并呋喃-7-基)双(2-甲氧苯基)膦
重复APEx4,但是变化为:添加7-溴-2,3-二氢苯并呋喃(350mg,1.76mmol)而不是8-溴色满,并且添加呈于THF(12mL)中的悬浮液形式的氯双(2-甲氧苯基)膦(444mg,1.76mmol)以产生白色结晶形式的APEx6(192mg,33%的产率)。
用1H、13C和31P核磁共振光谱法分析APEx6以证实形成。1HNMR(400MHz,CDCl3)δ7.33(t,J=7.7Hz,1H),7.18(d,J=7.2Hz,1H),6.92-6.81(m,2H),6.77-6.69(m,1H),6.56-6.48(m,1H),4.52(t,J=8.7Hz,1H),3.74(s,3H),3.21(t,J=8.7Hz,1H)。13CNMR(101MHz,CDCl3)δ162.76(d,J=18.1Hz),161.52(d,J=16.5Hz),133.72(s),132.12(s),130.04(s),126.08(d,J=2.8Hz),125.28(s),124.02(d,J=12.6Hz),120.88(s),120.53(s),116.39(d,J=14.2Hz),110.23(s),71.11(s),55.72(s),29.74(s)。31PNMR(162MHz,CDCl3)δ-40.23(s)。
APEx7:色满-8-基二苯基膦
重复APEx4,但是变化为:添加8-溴色满(500mg,2.35mmol),并且添加纯的二苯基氯化膦(0.434mL,2.35mmol)而不是氯双(2-甲氧苯基)膦以产生白色结晶形式的APEx7(429mg,57%的产率)。
用1H、13C和31P核磁共振光谱法分析APEx7以证实形成。1HNMR(400MHz,CDCl3)δ7.40-7.24(m,10H),7.06(d,J=7.4Hz,1H),6.75(t,J=7.5Hz,1H),6.52-6.41(m,1H),4.13(明显的t,J=5.1Hz,1H),2.82(t,J=6.5Hz,1H),2.06-1.87(m,1H);13CNMR(101MHz,CDCl3)δ156.64(d,J=15.5Hz),136.96(d,J=10.3Hz),133.92(d,J=20.0Hz),131.47(s),130.83(s),128.53(s),128.35(d,J=7.0Hz),124.55(d,J=11.5Hz),121.75(s),120.28(s),66.80(s),24.97(s),22.27(s);31PNMR(162MHz,CDCl3)δ-15.91(s)。
APEx8:双(2-甲氧苯基)(2,3,4,5-四氢苯并[b]噁庚因-9-基)膦
重复APEx4,但是变化为:添加9-溴-2,3,4,5-四氢苯并[b]噁庚因(200mg,0.88mmol)而不是8-溴色满,并且添加纯的二苯基氯化膦(0.19mL,1.01mmol)而不是氯双(2-甲氧苯基)膦以产生APEx8。
用1H、13C和31P核磁共振光谱法分析APEx8以证实形成。1HNMR(400MHz,CDCl3)δ7.53-7.44(m,10H),7.28(d,J=7.3Hz,1H),7.03(t,J=7.5Hz,1H),6.71(ddd,J=7.5,3.9,1.6Hz,1H),3.77(明显的t,J=5.0Hz,2H),2.97(dd,J=13.8,8.3Hz,2H),2.05-1.95(m,2H),1.86-1.76(m,2H);13CNMR(101MHz,CDCl3)δ162.39(d,J=16.6Hz),137.50(d,J=11.0Hz),136.76-136.42(m),135.79(d,J=1.0Hz),134.47(d,J=20.4Hz),131.75(s),131.36(s),130.77(d,J=9.2Hz),129.00(s),128.73(d,J=7.1Hz),123.87(s),3.29(s),34.68(d,J=1.2Hz),32.48(s),26.48(s);31PNMR(162MHz,CDCl3)δ-17.65(s)。
APEx9:三(2,3-二氢苯并呋哺-7-基)膦
重复APEx4,但是变化为:添加7-溴-2,3-二氢苯并呋喃(1.09g,5.49mmol)而不是8-溴色满,并且添加纯的三氯化磷(0.48mL,5.49mmol)而不是氯双(2-甲氧苯基)膦,以产生白色结晶形式的APEx9(356mg,53%的产率)。
用1H和31P核磁共振光谱法分析APEx9以证实形成。1HNMR(400MHz,CDCl3)δ7.18(dd,J=7.2,1.2Hz,1H),6.75(t,J=7.4Hz,1H),6.65-6.57(m,1H),4.53(t,J=8.7Hz,3H),3.20(t,J=8.7Hz,3H);31PNMR(162MHz,CDCl3)δ-45.71(d,J=34.6Hz)。
APEx10:P,P′-(9,9-二甲基-9H-氧杂蒽-4,5-二基)双[双(2,3-二氢苯并呋哺-7-基)膦)
在用N2净化过的干燥箱中,添加P,P′-(9,9-二甲基-9H-氧杂蒽-4,5-二基)双[N,N,N′,N′-四乙基-亚膦酸二酰胺](0.944g,1.69mmol)到玻璃瓶中。通过添加甲苯(60mL)来溶解玻璃瓶中的内含物。将所述玻璃瓶放置在用N2净化过的干燥箱冷冻机中-35℃下30分钟以冷却所述浅黄色溶液。从所述干燥箱冷冻机拿出玻璃瓶,并且添加氯化氢(2.0M乙醚溶液,9.0mL)到玻璃瓶的内含物中并且在23℃下搅拌一小时以形成白色沉淀。移取玻璃瓶内含物的等分试样,过滤,并且用31P核磁共振光谱法分析。在156ppm处的单峰证实形成了所需的P,P′-(9,9-二甲基-9H-氧杂蒽-4,5-二基)双(二氯化膦)。通过硅藻土过滤玻璃瓶的内含物,并且抽空至干燥以产生粘性白色残留物。用己烷(40mL)研磨所述粘性白色残留物以产生白色固体。在己烷(40mL)中悬浮所述白色固体,并且过滤。在真空下于23℃下干燥所述白色固体30分钟,以产生P,P′-(9,9-二甲基-9H-氧杂蒽-4,5-二基)双(二氯化膦)(0.455g,1.10mmol,65%的产率)。
将二氢苯并呋喃(2.60g)添加到具有涂覆PTFE的搅拌棒的第二玻璃瓶中。搅拌第二玻璃瓶的内含物,并且添加乙醚(40mL)以溶解二氢苯并呋喃。添加n-BuLi(9.0mL的2.5M己烷溶液)到第二玻璃瓶的内含物中,并且在23℃下搅拌48小时以产生橙色溶液和浅橙色沉淀。将玻璃瓶的内含物抽空至干燥以产生红色的油状物。添加己烷(20mL)到第二玻璃瓶中的红色油状物中并且搅拌以产生浅橙色的固体沉淀。从所述浅橙色的固体轻轻倒出己烷,并且在己烷(20mL)中洗涤所述浅橙色的固体。通过过滤收集所述浅橙色的固体,并且在真空下于23℃下干燥1小时以产生不纯的芳基锂盐(0.99g)。
添加一部分浅橙色的固体(0.55g)和THF(30mL)到第三玻璃瓶中以溶解浅橙色的固体,并且在干燥箱冷冻机中于-35℃下冷却第三玻璃瓶的内含物1小时。添加来自上一步骤的P,P′-(9,9-二甲基-9H-氧杂蒽-4,5-二基)双(二氯化膦)(0.455g,1.10mL)和THF(40mL)到第四玻璃瓶中,并且在干燥箱冷冻机中于-35℃下冷却1小时。从所述冷冻机中取出第三玻璃瓶和第四玻璃瓶。将第三玻璃瓶的内含物逐滴添加到第四玻璃瓶的内含物中,同时进行搅拌。使第四玻璃瓶的内含物加温到23℃,同时搅拌1小时。移取玻璃瓶内含物的等分试样,并且用31P核磁共振光谱法分析。所述光谱显示到所需APEx10的不完全转化。添加额外部分的浅橙色固体(0.30g)到第四瓶的内含物中,同时进行搅拌。移取第四瓶内含物的等分试样,并且用31P核磁共振光谱法分析。在-39ppm处的单峰证实形成了所需的APEx10。
用MeOH(2mL)淬灭反应混合物,并且抽空至干燥以产生米白色的残留物。在60℃下在MeOH(20mL)中悬浮米白色的残留物1小时,过滤,并且在23℃下在真空下干燥1小时以产生粘性固体。在甲苯(40mL)中溶解所述粘性固体,并且通过多孔玻璃漏斗过滤。将滤液抽空至干燥以形成米白色的残留物。用己烷(40mL)研磨米白色的残留物以产生米白色的粉末。在己烷(40mL)中悬浮米白色的粉末,过滤,并且在23℃下在真空下干燥1小时以得到APEx10(0.327g,0.438mmol,40%的产率)。
用1H、13C和31P核磁共振光谱法分析APEx10以证实形成。1HNMR(400MHz,C6D6)δ7.22-7.17(m,4H),7.16(brs,2H),7.09(dd,J=7.6Hz,J=1.6Hz,2H),6.91(dd,J=7.2Hz,J=1.2Hz,4H),6.85(t,J=7.6Hz,2H),6.71(t,J=7.6Hz,4H),4.06-3.89(m,8H),2.58-2.49(m,8H),1.34(s,6H);13C{1H}NMR(101MHz,C6D6)δ163.7(t,J=8.0Hz,Ar),153.7(t,J=10.2Hz,Ar)133.5(t,J=4.3Hz,ArH),133.2(s,ArH),130.2(m,Ar),126.8(s,ArH),126.7(m,Ar),125.5(s,ArH),123.6(s,ArH),121.1(s,ArH),118.1(d,J=18.3Hz),118.1(d,J=3.4Hz),71.0(s,CH2),34.8(s,C),32.5(s,CH2),30.1(s,CH3);31P{1H}NMR(162MHz,C6D6)δ-38.5(s)ppm。
APEx11:双(2,3-二氢苯并呋喃-7-基)氯化膦
在用N2净化过的干燥箱中将二氢苯并呋喃(2.60g)和涂覆PTFE的搅拌棒添加到玻璃瓶中。搅拌玻璃瓶的内含物,并且添加乙醚(40mL)以溶解二氢苯并呋喃。添加n-BuLi(9.0mL的2.5M己烷溶液)到玻璃瓶的内含物中,并且在23℃下搅拌48小时以形成浅橙色沉淀。过滤玻璃瓶的内含物,并且抽空至干燥以产生红色的油状物。添加己烷(20mL)到所述红色油状物中并且搅拌以产生浅橙色的固体沉淀。从所述浅橙色的固体轻轻倒出己烷,并且用己烷(20mL)洗涤,过滤,并且在23℃下在真空下干燥1小时以产生不纯的芳基锂盐(0.75g)。在第二玻璃瓶中用THF(50mL)溶解一部分不纯的芳基锂盐(0.69g),并且在干燥箱冷冻机中-35℃下冷却1小时。将二甲基氯化磷胺(0.30mL,2.6mmol)逐滴添加到第二玻璃瓶的内含物中。使第二玻璃瓶的内含物加温到23℃并且搅拌一小时。移取玻璃瓶内含物的等分试样,并且用31P核磁共振光谱法分析。所述光谱显示到所需双(2,3-二氢苯并呋喃-2-基)二甲氨基膦的转化(46.8ppm,82%的产率)。还存在作为杂质的(2,3-二氢苯并呋喃-7-基)(二甲氨基)氯化膦(125.5ppm,14%)。
将所述反应混合物抽空至干燥并且用己烷(40mL)研磨以产生白色残留物。在甲苯(60mL)中搅拌浆化白色残留物,并且通过硅藻土过滤以去除LiCl。将第三玻璃瓶中的甲苯滤液放置在干燥箱冷冻机中-35℃下30分钟。添加氯化氢(2.0M乙醚溶液,2.8mL)到第三玻璃瓶的内含物中,同时进行搅拌。使第三玻璃瓶的内含物加温到23℃,并且搅拌一小时以形成白色沉淀。移取反应混合物的等分试样,过滤,并且用31P核磁共振光谱法分析。所述光谱显示到所需APEx11的转化(66ppm)。通过硅藻土过滤所述反应混合物,并且抽空至干燥。在己烷(40mL)中研磨所得的黄色油状物以产生米白色的固体。在己烷(40mL)中搅拌浆化米白色的固体,通过过滤收集,并且在23℃在真空下干燥1小时以产生APEx11(0.171g,0.561mmol,产率22%)。
用1H、13C和31P核磁共振光谱法分析APEx11以证实形成。1HNMR(400MHz,C6D6)δ7.61-7.57(m,2H),6.84(dq,J=7.6Hz,J=1.2Hz,2H),6.73(t,J=8.0Hz,2H),3.87(t,J=8.8Hz,4H),2.35(t,J=8.8Hz,4H);13C{1H}NMR(101MHz,C6D6)δ163.0(d,J=20.0Hz,Ar),131.5(d,J=7.3Hz,ArH),127.7(d,J=1.7Hz,Ar),127.6(s,ArH)121.3(s,ArH),118.6(d,J=38.0Hz,Ar),71.8(s,CH2),29.5(s,CH2);31P{1H}NMR(162MHz,C6D6)δ66.6(s)ppm。
过渡金属络合物(TMC)
TMCEx1:乙酰丙酮[二环己基(2,3-二氢苯并呋喃-7-基)膦]铑(I)
如下所述制备TMCEx1:在用N2净化的干燥箱中将APEx3(0.039g,0.12mmol)添加到小玻璃管中。将C6D6(1mL)添加到所述小玻璃管中以完全溶解APEx3。在第二小玻璃管中,添加乙酰丙酮二羰基铑(I)(0.032g,0.12mmol)。将第一小玻璃管的内含物添加到第二小玻璃管中以产生黄色溶液。注意到CO气体从溶液中逸出,指示形成了膦铑络合物。将小玻璃管中的溶液转移到NMR试管中并且通过1H和31P核磁共振光谱法进行分析。31PNMR指示到TMCEx1的接近定量转化(大于97%)。将NMR样本返回到用N2净化过的干燥箱中并且转移到第三小玻璃管中。使用3mL的THF来洗涤NMR试管并且将洗涤液转移到小玻璃管中。在真空下去除溶剂。添加2mL的己烷到小玻璃管中,并且在真空下去除溶剂。重复。在1mL的己烷中浆化所得的浅黄色粉末,并且放置在干燥箱冷冻机中-35℃下1小时。通过过滤收集浅黄色粉末,并且在真空下干燥1小时以得到TMCEx1(0.020g,0.039mmol,31%)。
用1H、13C和31P核磁共振光谱法分析TMCEx1以证实形成。1HNMR(400MHz,C6D6)δ8.25(dd,J=7.2Hz,J=12.0Hz,1H),6.86(m,1H),6.76(td,J=0.8Hz,J=7.6Hz,1H),5.38(s,1H),3.91(t,J=8.8Hz,2H),2.92(m,2H),2.42(t,J=8.8Hz,2H),2.24(m,2H),1.97(s,3H),1.95(m,2H),1.78(s,3H),1.74-1.55(m,10H),1.42-1.23(m,4H),1.08(m,2H);13C{1H}NMR(101MHz,C6D6)δ191.5(dd,J=23.5Hz,J=77.0Hz),188.5(s),184.7(s),161.9(s),140.1(d,J=17.9Hz),127.7(d,J=2.2Hz),127.3(d,J=4.1Hz),120.6(d,J=11.3Hz),111.2(d,J=43.0Hz),101.0(d,J=2.3Hz),71.3(s),33.7(s),33.4(s),30.3(d,J=3.7Hz),29.6(s),29.2(d,J=1.9Hz),28.1(dd,J=1.0Hz,J=5.2Hz),27.9(d,J=4.3Hz),27.8(d,J=7.8Hz),27.5(m),27.0(d,J=1.3Hz);31P{1H}NMR(162MHz,C6D6)δ64.3(d,J=174.6Hz)ppm。
TMCEx2:氯化烯丙基[二叔丁基(2,3-二氢苯并呋喃-7-基)膦]钯(II)
如下所述制备TMCEx2:在用N2净化的干燥箱中将APEx1(0.051g,0.19mmol)添加到小玻璃管中。将C6D6(1mL)添加到所述小玻璃管中以完全溶解APEx1。在第二小玻璃管中,添加氯化烯丙基钯(II)二聚体(0.035g,0.096mmol)。将第一小玻璃管的内含物添加到第二小玻璃管中以产生黄色溶液。将小玻璃管中的溶液转移到NMR试管中并且通过1H和31P核磁共振光谱法进行分析。31PNMR指示到TMCEx2的定量转化。将NMR样本返回到用N2净化过的干燥箱中并且转移到第三小玻璃管中。使用5mL的THF来洗涤NMR试管并且将洗涤液转移到小玻璃管中。在真空下去除溶剂。添加2mL的己烷到小玻璃瓶中,并且在真空下去除溶剂。在1mL的己烷中浆化所得的黄色粉末,并且通过过滤收集粉末。在真空下干燥黄色粉末1小时以得到TMCEx2(0.039g,0.087mmol,91%)。
用1H、13C和31P核磁共振光谱法分析TMCEx1以证实形成。1HNMR(400MHz,CD2Cl2)δ7.48(m,1H),7.28(m,1H),6.85(t,J=7.2Hz,1H),5.48(m,1H),4.51(m,3H),3.60(dd,J=9.2Hz,J=13.6Hz,1H),3.34(brs,1H),3,22(t,J=8.4Hz,2H),2.67(brs,1H),1.42(brs,18H);13C{1H}NMR(101MHz,CD2Cl2)δ161.1(s),137.1(brs),127.8(d,J=2.9Hz),127.1(d,J=1.8Hz),119.3(d,J=10.2Hz),115.0(d,J=4.7Hz),12.9(d,J=24.5Hz),78.8(d,J=29.7Hz),70.7(s),58.3(s),36.4(brs),29.7(brd,J=94.8Hz),29.4(s);31P{1H}NMR(162MHz,CD2Cl2)δ77.7(brs)ppm。
丁二烯调聚反应(BT)
使用APEx5的BTEx1
在手套箱中,在脱气的MeOH中溶解脱气的冰醋酸(AcOH)(55.3μL)达到5mL体积(0.1932MAcOH的MeOH溶液),以形成AcOH溶液。将乙酰丙酮钯(II)(Pd(acac)2)(0.0147g,0.0000483摩尔)、APEx5和0.25mL的AcOH溶液溶解在MeOH中达到总体积25mL,以形成预催化剂储备溶液。将丁醚(Bu2O,5mL)、MeOH(10.96mL)、无水脱气的甲基环己烷(MeCy,1.6mL)、所述预催化剂储备溶液(1mL),以及一部分的甲醇钠(NaOMe)在MeOH中的溶液(0.01932M)(1.0mL)添加到菲时博特(Fisher-Porter)瓶中。一般说来,所述反应是用MeOH(12.8M)进行的。用装配有隔膜口的阀密闭所述菲时博特瓶。在手套箱外部将丁二烯(5mL)蒸馏到气密的注射器中。通过称量在添加到所述菲时博特瓶前后所述注射器的重量来测定丁二烯的质量。用安插在溶液表面以下的针将丁二烯注射到所述菲时博特瓶中(5mL,其中每次注射的精确重量是通过称量注射前后注射器的重量并且取前后重量的差值而计算出的)。将所述反应器放置在加热到60℃的油浴中,搅拌并且反应4小时。通过装配有气密阀的24″针移取等分试样并执行GC分析。
使用APEx5的BTEx2
重复BTEx1,但是变化为:将油浴加热到90℃。
使用APEx5的BTEx3
重复BTEx1,但是变化为:将油浴加热到40℃。
使用APEx4的BTEx4
重复BTEx3,但是变化为:使用APEx4而不是APEx5。
使用APEx4的BTEx5
重复BTEx1,但是变化为:使用APEx4而不是APEx5。
使用APEx6的BTEx6
重复BTEx1,但是变化为:使用APEx6而不是APEx5。
使用APEx6的BTEx7
重复BTEx2,但是变化为:使用APEx6而不是APEx5。
使用APEx7的BTEx8
重复BTEx1,但是变化为:使用APEx7而不是APEx5。
使用APEx7的BTEx9
重复BTEx2,但是变化为:使用APEx7而不是APEx5。
使用APEx9的BTEx10
重复BTEx3,但是变化为:使用APEx9而不是APEx5。
使用APEx9的BTEx11
重复BTEx1,但是变化为:使用APEx9而不是APEx5。
使用APEx6的BTEx12
重复BTEx3,但是变化为:使用APEx6而不是APEx5。
使用三(2-甲氧苯基)膦的比较实例1(CompEx1)
重复BTEx2,但是变化为:使用三(2-甲氧苯基)膦而不是APEx5。
使用(2-甲氧苯基)二苯基膦的比较实例2(CompEx2)
重复BTEx2,但是变化为:使用(2-甲氧苯基)二苯基膦而不是APEx5。
转化率(Conv)是所转化的丁二烯的摩尔数除以进料到反应器中的丁二烯的摩尔数。MOD-1(1-甲氧基-2,7-辛二烯)是MOD-1的摩尔数除以所产生的所有产物的摩尔数。MOD-3(3-甲氧基-1,7-辛二烯)是MOD-3的摩尔数除以所产生的所有产物的摩尔数。L/B比率是MOD-1的摩尔数除以MOD-3的摩尔数。催化剂效率是MOD-1的克数除以Pd的克数除以反应时间的小时数。关于三(2-甲氧苯基)膦(CompEx1)和(2-甲氧苯基)二苯基膦(CompEx2)的数据源自WO2010/019360(A2)并且被包括作为比较实例。
表1
表1中的数据显示使用APEx4、APEx5、APEx6、APEx7和APEx8的丁二烯调聚反应。此表还包括关于作为CompEx1的三(2-甲氧苯基)膦和作为CompEx2的(2-甲氧苯基)二苯基膦的数据。此表表明用稠环邻烷氧基取代代替邻甲氧苯基在有些情况中可提高催化剂效率。举例来说,BTEx2相较于CompEx2表现出催化剂效率的提高;BTEx11相较于CompEx1表现出催化剂效率的提高,并且BTEx10相较于BTEx12表现出催化剂效率的提高。
Claims (11)
1.一种式(I)的芳基膦,
其中n是1至3范围内的整数,其中R1和R3独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R2和R2′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R4、R5、R6和R7独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳的经取代或者未经取代的环烷基、卤素,以及经取代或者未经取代的苯环组成的群组,其中R1、R2、R2′、R3、R4、R5、R6和R7上可容许的取代基是包括选自由氧、氮、卤素、硫、硼、磷和硅组成的群组的杂原子的官能团。
2.如权利要求1所述的芳基膦,其中R4和R5独立地选自由甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、金刚烷基、苯基、联苯基,以及环己基组成的群组。
3.如权利要求1所述的芳基膦,其中R4和R5与磷原子一起形成5员、6员或者7员环。
4.如权利要求1所述的芳基膦,其中R4和R5独立地选自由式(II)至式(X)组成的群组:
其中m是1或者2,其中Q1、Q2和Q5独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基、具有3至18个碳的经取代或者未经取代的环烷基、卤素,以及经取代或者未经取代的苯环组成的群组,Q3选自由H、具有1至18个碳的经取代或者未经取代的烷基、以及经取代或者未经取代的苯环组成的群组,Q4和Q4′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中u是在0至2范围内的整数,其中v是在0至2范围内的整数,并且其中当R4和R5都是式(X)时,R4和R5任选地在式(X)中相应C原子的邻位处共价键结在一起。
5.如权利要求1所述的芳基膦,其中所述芳基膦选自由以下各项组成的群组:
6.一种式(I)的芳基膦,
其中n是在1至3范围内的整数,其中R1和R3独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R2和R2′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R4选自由H、具有1至18个碳的经取代或者未经取代的烷基、卤素、具有3至18个碳的经取代或者未经取代的环烷基,以及经取代或者未经取代的苯环组成的群组,其中R1、R2、R2′、R3、R4、R6和R7上可容许的取代基是包括选自由氧、氮、卤素、硫、硼、磷和硅组成的群组的杂原子的官能团,并且其中R5是桥连基,其包含芳环并且将所述式(I)的芳基膦连接至第二膦。
7.如权利要求6所述的芳基膦,其中R5和所述第二膦一起形成选自由式(II)至式(IV)组成的群组的结构:
8.一种式(I)的芳基膦,
其中n是在1至3范围内的整数,其中R1和R3独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R2和R2′各自独立地选自由H、具有1至18个碳的经取代或者未经取代的烷基,以及经取代或者未经取代的苯环组成的群组,其中R4选自由H、具有1至18个碳的经取代或者未经取代的烷基、卤素、具有3至18个碳的经取代或者未经取代的环烷基,以及经取代或者未经取代的苯环组成的群组,其中R1、R2、R2′、R4、R6和R7上可容许的取代基是包括选自由氧、氮、卤素、硫、硼、磷、氟和硅组成的群组的杂原子的官能团,并且其中R5是选自由式(II)至式(X)组成的群组的桥连基:
其中Z是所述式(I)的芳基膦,其中R8和R9独立地选自由H和具有4个碳的烷基组成的群组,其中R10选自由C和S组成的群组,其中R11选自由O和S组成的群组,其中R12、R13、R14和R15各自独立地选自由C和O组成的群组,其中R16选自由N和C组成的群组,限制条件是当R16是N时则R14和R15是C。
9.如权利要求8所述的芳基膦,其中所述芳基膦具有下式:
10.如权利要求1到权利要求9中任一项所述的芳基膦,其中所述芳基膦是过渡金属的配体,所述过渡金属选自由钛(Ti)、铜(Cu)、钯(Pd)、钴(Co)、铑(Rh)、钌(Ru)、铬(Cr)和铂(Pt)组成的群组。
11.一种配体,其包含:
如权利要求1到权利要求9中任一项所述的芳基膦;以及
过渡金属,其选自由钛(Ti)、铜(Cu)、钯(Pd)、钴(Co)、铑(Rh)、钌(Ru)、铬(Cr)和铂(Pt)组成的群组。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361837475P | 2013-06-20 | 2013-06-20 | |
US61/837475 | 2013-06-20 | ||
PCT/US2014/042846 WO2014205025A1 (en) | 2013-06-20 | 2014-06-18 | Aryl phosphines with fused ring ortho-alkoxy substitution |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105324387A true CN105324387A (zh) | 2016-02-10 |
Family
ID=51168440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480034103.8A Pending CN105324387A (zh) | 2013-06-20 | 2014-06-18 | 具有稠环邻烷氧基取代的芳基膦 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9579641B2 (zh) |
EP (1) | EP3010927A1 (zh) |
CN (1) | CN105324387A (zh) |
CA (1) | CA2914576A1 (zh) |
WO (1) | WO2014205025A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110960A1 (en) * | 2001-03-29 | 2004-06-10 | Wolfgang Ahlers | Ligands for pnicogen chelate complexes with a metal of subgroup VIII and use of the complexes as catalysts for hydroformylation, carbonylation, hydrocyanation or hydrogenation |
CN1592725A (zh) * | 2001-11-09 | 2005-03-09 | 国际壳牌研究有限公司 | 二烯调聚反应的双齿配位体 |
CN101415717A (zh) * | 2006-04-04 | 2009-04-22 | 可乐丽股份有限公司 | 使用双亚磷酸酯和第8-10族金属化合物制备醛的方法以及该双亚磷酸酯 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013096631A1 (en) | 2011-12-23 | 2013-06-27 | Dow Global Technologies Llc | Ligands for rhodium catalyzed reductive carbonylation of alcohols |
-
2014
- 2014-06-18 CN CN201480034103.8A patent/CN105324387A/zh active Pending
- 2014-06-18 US US14/899,715 patent/US9579641B2/en not_active Expired - Fee Related
- 2014-06-18 WO PCT/US2014/042846 patent/WO2014205025A1/en active Application Filing
- 2014-06-18 EP EP14737457.3A patent/EP3010927A1/en not_active Withdrawn
- 2014-06-18 CA CA2914576A patent/CA2914576A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110960A1 (en) * | 2001-03-29 | 2004-06-10 | Wolfgang Ahlers | Ligands for pnicogen chelate complexes with a metal of subgroup VIII and use of the complexes as catalysts for hydroformylation, carbonylation, hydrocyanation or hydrogenation |
CN1592725A (zh) * | 2001-11-09 | 2005-03-09 | 国际壳牌研究有限公司 | 二烯调聚反应的双齿配位体 |
CN101415717A (zh) * | 2006-04-04 | 2009-04-22 | 可乐丽股份有限公司 | 使用双亚磷酸酯和第8-10族金属化合物制备醛的方法以及该双亚磷酸酯 |
Non-Patent Citations (1)
Title |
---|
MATHIEU J L T. ET AL: ""Large P-P Distance Diphosphines and Their Monophosphine Analogues as Ligands in the Palladium-Catalyzed Telomerization of 1,3-Butadiene and Methanol"", 《ORGANOMETALLICS》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014205025A1 (en) | 2014-12-24 |
US9579641B2 (en) | 2017-02-28 |
US20160184811A1 (en) | 2016-06-30 |
EP3010927A1 (en) | 2016-04-27 |
CA2914576A1 (en) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sun et al. | Synthesis and characterization of novel nickel (II) complexes bearing N, P ligands and their catalytic activity in ethylene oligomerization | |
Mehring et al. | Syntheses, characterizations, and single-crystal X-ray structures of soluble titanium alkoxide phosphonates | |
CN101990543B (zh) | 制备钌卡宾络合物的方法 | |
CN104136450B (zh) | 含鎓基的复分解催化剂 | |
Brassat et al. | Synthesis and characterization of homologous nickel (II) and palladium (II) complexes with biphosphine monoxide ligands Ph2P (CH2) nP (O) Ph2 (n= 1–3) and pTol2P (CH2) P (O) pTol2 | |
CN102007136A (zh) | 含咪唑基的磷化合物 | |
CN110088114A (zh) | 一种制备酰基膦的通用方法 | |
Majhi et al. | Synthesis and first complexes of C 4/5 P-bifunctional imidazole-2-thiones | |
Jankowska-Wajda et al. | Platinum and rhodium complexes ligated by imidazolium-substituted phosphine as efficient and recyclable catalysts for hydrosilylation | |
Guillemin et al. | Synthesis of Nonstabilized Phosphaalkynes by Vacuum Gas‐Solid HCl Elimination | |
JP2001506644A (ja) | 遷移金属化合物および4,5−ジホスフィノアクリジン配位子から作製される新規触媒 | |
Esquius et al. | Synthesis of Ru (II) complexes of the new 1-[(P-diphenyl)-2-phosphinoethyl]-3, 5-dimethylpyrazole ligand and study of their reactivity toward terminal alkynes | |
Croxtall et al. | Synthesis and coordination chemistry of ortho-perfluoroalkyl-derivatised triarylphosphines | |
CN105324387A (zh) | 具有稠环邻烷氧基取代的芳基膦 | |
Miranda et al. | Palladium and platinum pyrimidine-2-thionate complexes with diphosphines | |
CN112812064B (zh) | 手性二苯并[e,g][1,4]二氮杂环辛四烯配体及其制备方法 | |
CN104136117A (zh) | 用于醇的铑催化的还原性羰基化反应的配体 | |
EP2842959A1 (en) | Phosphorous compound and transition metal complex thereof | |
WO2011045417A1 (en) | Triphenylphosphine derivatives | |
JP5791040B2 (ja) | ホスフィン化合物およびホスフィン含有有機無機複合材料とその利用 | |
Godoy et al. | Reaction of tetramenthylfulvene rhenium complexes (η6-c5me4ch 2) re (co) 2r (r= i, c6f5) with alkyl phosphines and trimethylphosphite: X-ray structure of [(η5-c5me4ch 2-(pme3)) re (co) 2 (pme3)]+ i | |
JPH08183791A (ja) | ビス−ホスフェピン及びその製造方法 | |
US10093690B2 (en) | Heterocyclic selenaphosphites and process for preparation thereof | |
Karami et al. | X-ray and Spectroscopy Studies of Mercury (II) and Silver (I) Complexes of α-Ketostabilized Phosphorus Ylides | |
US20120142918A1 (en) | Ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160210 |